PDCD1 and hepatocellular carcinoma: Although clinical immunotherapy (such as anti-PD-1, anti-PD-L1, and anti-CTLA-4) for HCC has been widely used for HCC worldwide (62, 63), only a minority of patients benefited from immunotherapy.